Nastorazepide: A Novel CCK-2 Receptor Antagonist for Pancreatic Cancer Research and Treatment
Exploring the therapeutic potential of Nastorazepide in targeted cancer therapies and pain management.
Get a Quote & SampleProduct Core Value
Nastorazepide
Nastorazepide, also known as Z-360, is a highly selective CCK-2 receptor antagonist with significant potential in the field of oncology. It exhibits oral activity and targets the gastrin/cholecystokinin-2 receptor, a key player in the proliferation of various tumor cells, including pancreatic cancer. Its ability to inhibit gastrin-induced proliferation makes it a valuable agent in cancer research and treatment development.
- This compound is a critical tool for researchers studying the role of CCK-2 receptor antagonists in cancer therapy.
- Leveraging Nastorazepide for pancreatic cancer treatment shows promising results in preclinical models.
- Understanding the Nastorazepide mechanism of action is key to developing new therapeutic strategies.
- The API form of Nastorazepide is crucial for pharmaceutical development and clinical trials.
Key Advantages
Targeted Action
Nastorazepide’s high selectivity for the CCK-2 receptor ensures targeted therapeutic effects, minimizing off-target interactions and enhancing efficacy in pancreatic cancer treatment.
Oral Bioavailability
The oral activity of Nastorazepide simplifies administration, making it a more convenient option for patient treatment and clinical studies, a significant aspect of pharmaceutical API research.
Therapeutic Versatility
Beyond its direct antitumor effects, Nastorazepide demonstrates potential in pain management and in inhibiting liver metastasis of colorectal cancer, showcasing its broad application in novel oncology drug discovery.
Key Applications
Oncology Research
Investigating the therapeutic potential of Nastorazepide in various cancers, particularly pancreatic cancer, by understanding its anti-proliferative effects and interaction with CCK-2 receptors.
Pharmaceutical Development
Utilizing Nastorazepide as an Active Pharmaceutical Ingredient (API) in the development of new drug formulations and treatment protocols for gastrointestinal and pancreatic malignancies.
Targeted Therapy
Exploring Nastorazepide’s role in targeted therapy approaches, focusing on its ability to inhibit gastrin-driven tumor growth and its combination potential with other chemotherapeutic agents.
Pain Management in Cancer
Examining the efficacy of Nastorazepide in alleviating cancer-related pain, leveraging its pharmacological properties to improve patient quality of life.